JNJ · News · 20260817N
Acquisition / Partnership / Divestiture
JOHNSON & JOHNSON · 2026-08-17 · Importance 64 · Surprise 42 · Contradicted
Johnson & Johnson secured an exclusive option to acquire Sail Biomedicines for $2.58 billion, including an initial $785 million payment. The transaction supports Sail’s in vivo CAR T platform for immune-mediated diseases and could generate additional development milestone payments. Sail’s lead asset, SAIL-0839, remains in preclinical development, with the platform intended to reprogram immune cells inside patients rather than use ex vivo manufacturing.
Key facts
- Johnson & Johnson has secured an exclusive option to acquire Sail Biomedicines for $2.58 billion. source
- Initial payments from Johnson & Johnson to Sail Biomedicines total $785 million. source
- Johnson & Johnson may pay additional amounts to Sail Biomedicines upon achieving development milestones (amount unspecified). source
- Johnson & Johnson has hired Forbes Tate Partners LLC as its new lobbying firm to lobby on healthcare issues including Medicare and Medicaid matters. source
- Sail Biomedicines' lead asset, SAIL-0839, remains in preclinical development according to the report. source
- Forbes Tate Partners LLC has three partners assigned to the Johnson & Johnson lobbying account. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -0.3% | Initial payments from Johnson & Johnson to Sail Biomedicines total $785 million. |
| assets | positive | committed | +0.3% | Initial payments from Johnson & Johnson to Sail Biomedicines total $785 million. |
| liability | negative | contingent | -0.2% | Johnson & Johnson has secured an exclusive option to acquire Sail Biomedicines for $2.58 billion. |